Publication: Current peptide and protein candidates challenging HIV therapy beyond the vaccine Era
Issued Date
2017-10-01
Resource Type
ISSN
19994915
DOI
Other identifier(s)
2-s2.0-85030563444
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Viruses. Vol.9, No.10 (2017)
Suggested Citation
Koollawat Chupradit, Sutpirat Moonmuang, Sawitree Nangola, Kuntida Kitidee, Umpa Yasamut, Marylène Mougel, Chatchai Tayapiwatana Current peptide and protein candidates challenging HIV therapy beyond the vaccine Era. Viruses. Vol.9, No.10 (2017). doi:10.3390/v9100281 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42750
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Current peptide and protein candidates challenging HIV therapy beyond the vaccine Era
Other Contributor(s)
Abstract
© 2017 by the authors.Licensee MDPI, Basel, Switzerland. Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected patients. However, drug toxicities and poor drug administration has led to the emergence of a drug-resistant strain. HIV-1 immunotherapy has been continuously developed, but antibody therapy and HIV vaccines take time to improve its efficiency and have limitations. HIV-1-specific chimeric antigen receptor (CAR)- based immunotherapy founded on neutralizing antibodies is now being developed. In HIV-1 therapy, anti-HIV chimeric antigen receptors showed promising data in the suppression of HIV-1 replication; however, autologous transfusion is still a problem. This has led to the development of effective peptides and proteins for an alternative HIV-1 treatment. In this paper, we provide a comprehensive review of potent anti-HIV-1 peptides and proteins that reveal promising therapeutic activities. The inhibitory mechanisms of each therapeutic molecule in the different stages of the HIV- 1 life cycle will be discussed herein.